S2 Ep22: Can GLP-1 Therapy Revolutionize Chronic Skin Treatment?

S2 Ep24: Debunking Allergy Myths and the Future of Atopic Dermatitis Treatment

In this episode of The Cutaneous Connection, Dermatology Times revisits a recent video episode of the Derm Dispatch show where host Renata Block, DMSc, MMS, PA-C, sits down with Zachary Rubin, MD — allergist, pediatrician, and New York Times bestselling author of All About Allergies — to explore the intersection of dermatology and allergy. Together, they tackle one of the most persistent myths in practice: that food elimination can treat atopic dermatitis. Dr. Rubin breaks down the difference between IgE-mediated allergic reactions and the complex inflammatory nature of eczema, explains the atopic march, and discusses how understanding the gut-lung-skin axis can empower patients to take charge of their care. The conversation also covers the latest treatment advances — from JAK inhibitors to novel biologics — and touches on indolent systemic mastocytosis and the truth about so-called hypoallergenic dogs. A must-listen for any clinician treating allergic and inflammatory skin disease. For more content, visit https://www.dermatologytimes.com/ [https://www.dermatologytimes.com/]

S2 Ep23: Diving Into the Safety and Efficacy of Icotrokinra, the New Oral IL-23 Peptide in Psoriasis

Join Dermatology Times for a conversation with Liza O'Dowd, MD, vice president of immunodermatology and respiratory disease areas at Johnson & Johnson, recorded at the 2026 AAD Annual Meeting. Dr. O'Dowd discusses one-year efficacy and safety data for icotrokinra (Icotyde), the newly approved once-daily oral peptide IL-23 receptor antagonist for moderate to severe plaque psoriasis in adults and adolescents 12 and older. At 52 weeks, approximately 50% of adult patients achieved total skin clearance, rising to 60% in adolescents enrolled in the LEAD study. Adverse event rates through one year remained within 1.1% of placebo, with no mandatory tuberculosis pre-screening required. Dr. O'Dowd also addresses icotrokinra's anticipated role as a first-line systemic therapy and offers practical reassurance for clinicians considering this novel agent for their patients. For more content from Dermatology Times, visit https://www.dermatologytimes.com/ [https://www.dermatologytimes.com/]

S2 Ep22: Can GLP-1 Therapy Revolutionize Chronic Skin Treatment?

In this episode, board-certified dermatologist of US Dermatology Partners, Daniel Walker, MD, FAAD, shares emerging insights into the expanding role of GLP-1 receptor agonists beyond their primary use in diabetes and weight loss, highlighting their promising—yet still investigational—impact on inflammatory skin diseases such as psoriasis and HS.

S2 Ep21: By the Skin of Your Teeth with The Spizuoco Sisters

In this conversation, identical twin practitioners—dermatologist Amy Spizuoco, DO, FAOCD, and dentist Stacy Spizuoco, DDS,—discuss how dentistry and dermatology intersect in shared patients, from oral lesions and skin conditions to cosmetic collaborations that brighten and rejuvenate smiles “by the skin of your teeth.”

S2 Ep20: Skin Changes, Hormones, and the Menopause Conversation in Aesthetics

In this episode, we sat down with Doris Day, MD, a board-certified dermatologist in New York City, who's 25-year long career focuses on longevity aesthetics. She discussed the most common cutaneous concerns among menopausal women, insights from Galderma’s recent menopause survey, and how dermatologists can thoughtfully incorporate conversations about hormonal health into aesthetic consultations.